The monoclonal antibody (mAb) therapeutics market is growing at a rapid rate owing to
increased demand for targeted treatments. Therapeutic mAbs, such as Rituxan, Herceptin, Remicade, and Avastin, are mostly produced from mammalian cells. These
biological products are heterogeneous due to post-translational modifications.
Additional modifications such as oxidation can be introduced during the manufacturing